Open AccessModern possibilities of application <sup>99m</sup>Tc-labeled prostate-specific membrane antigen ligands in prostate cancer
Author(s) -
A. V. Leontyev,
А. И. Халимон,
М. Т. Кулиев,
A. Y. Govaleshko,
А. Д. Каприн,
А. А. Крашенинников,
K. M. Nyushko,
А. S. Kalpinskiy,
B. Ya. Alekseev
Publication year - 2022
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2021-17-4-136-150
Subject(s) - glutamate carboxypeptidase ii , medicine , prostate cancer , prostate , nuclear medicine , cancer
This article presents a modern possibilities and future path of prostate-specific membrane antigen (PSMA) radiopharmacuticals labeled by 99m Tc, that is the most popular isotope using in conventional nuclear medicine. The main advantages and disadvantages of SPECT/CT with these radiopharmaceuticals in different phases of prostate cancer continuum have been analyzed. Results of research diagnostic sensitivity of 99m Tc-PSMA SPECT/CT including comparison with 68 Ga-PSMA PET/CT and conventional modality such as MRI and bone scan are presented. The prerequisites of application 99m Tc-labeled PSMA ligands in PSMA-guided surgery, methodology of PSMA-guided surgery and foreign authors application experience are presented in this article too.